Background: The choice of empirical antibiotic treatment for patients with community-
acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Background: We investigated whether the use of respiratory fluoroquinolones was
associated with better clinical outcomes compared with the use of macrolides and β-lactams …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Background There are several antibiotic regimens to treat community-acquired pneumonia
(CAP). Research Question In patients hospitalized to a non-ICU ward setting with CAP, is …

Objective The best treatment option for hospitalized patients with community-acquired
pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone …

Objectives This network meta-analysis aimed to compare the efficacy and safety of
fluoroquinolone (FQ) monotherapy, β-lactam (BL) monotherapy and β-lactam/macrolide (BL …

Background. Macrolides are used to treat pneumonia despite increasing antimicrobial
resistance. However, the immunomodulatory properties of macrolides may have a favorable …

OBJECTIVE: To determine the role of newer fluoroquinolones (FQs) for adults with
community-acquired pneumonia (CAP) whose level of illness allows treatment with an oral …

Fluoroquinolone use has dramatically increased since the introduction of the first respiratory
fluoroquinolone in the late 1990s. Over a relatively brief period of time, the respiratory …